113459-58-8

Upstream product

• 574-98-1 2-(2-bromoethyl)isoindoline-1,3-dione 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 3891-07-4 N-(2-Hydroxyethyl)phthalimide 
• 56850-91-0 methyl 4-(2-bromoethoxy)benzoate 
• 1074-82-4 potassium phtalimide 

Downstream Products

• 174665-29-3 3-{4-[2-(pyrimidin-2-ylamino)ethyloxy]benzoylamino}-2(S)-benzenesulfonylaminopropionic acid tert-butyl ester 
• 174665-30-6 3-{4-[2-(pyrimidin-2-ylamino)ethyloxy]benzoylamino}-2(S)-benzenesulfonylaminopropionic acid 
• 174665-27-1 methyl 4-[2-(pyrimidin-2-ylamino)ethyloxy]benzoate 
• 174665-28-2 4-[2-(pyrimidin-2-ylamino)ethyloxy]benzoic acid 
• 56850-93-2 methyl 4-(2-Aminoethyloxy)benzoate 

Relevant academic research and scientific papers

USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

The invention relates to the use of imidazole derivatives of the formula (I): in which A, R'1, R'2 and R'3 are as defined in the description, as AMPK activators. The invention also relates to processes for the preparation of the said compounds, to their uses for the preparation of medicaments for the treatment of insulin resistance, diabetes and related pathologies, and also obesity, and to the pharmaceutical compositions comprising them. Certain compounds of the formula (I) are novel and, in this respect, also form part of the invention.

Nonpeptide α(v)β3 antagonists. 1. Transformation of a potent, integrin-selective α(IIb)β3 antagonist into a potent α(v)β3 antagonist

Modification of the potent fibrinogen receptor (α(IIb)β3) antagonist 1 generated compounds with high affinity for the vitronectin receptor α(v)β3. Sequential modification of the basic N-terminus of 1 led to the identification of the

Synthesis and activities of new arylsulfonamido thromboxane A2 receptor antagonists

New benzoic, benzeneacetic and thiazole-4-acetic acids bearing an arylsulfonamido alkyl or alkylhetero side chain were synthesized and tested in vitro for affinity for human platelet thromboxane A2 receptors and inhibition of U46619-induced rat aortic ring contraction.Influence of substitution patterns, chain length and presence of heteroatoms were studied and compounds within a 30 nmol range for inhibition of U46619-induced contractions were found.One of the most potent, 2-thiazole-4-acetic acid (VII-4) was orally active (1 mg/kg), as evidenced by the inhibition of U46619-induced platelet aggregation in guinea pigs, ex vivo. thromboxane A2 / receptor antagonist / platelet aggregation / arylsulfonamido derivative

Benzoic acid derivatives

Compounds of formula (I) STR1 or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen, halogen or alkyl and R2 is hydrogen or alkyl are useful to reduce serum lipids in animals, including humans.